PharmaEssentia Corp (6446) Stock Price & News

6446:TPE

PharmaEssentia Corp

NT$1,185.00

-5.20%

(-65.00) 1D

Nov 5, 1:30:07 PM GMT+8 · TWD

All symbols

	Symbol	Price	Change	% Change

Next call in 4 days

Mon, Nov 9, 6:00 AM

Fiscal period

Q3 2026

- / NT$6.51

Revenue / Est. (TWD)

- / 7.69B

Fiscal Q3 2026 earnings call

Waiting for the earnings call

At a glance: upcoming earnings

Insights from the latest news and reports

Previous reportsAll values in TWD

Loading Previous Earnings...

All values in TWD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	3.89B	4.88B	5.12B	6.86B
Cost of goods sold	327.93M	543.68M	621.28M	395.45M
Cost of revenue	327.93M	543.68M	621.28M	395.45M
Research and development expenses	884.63M	1.01B	857.29M	1.07B
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	1.52B	1.77B	1.56B	2.24B
Operating expense	2.40B	2.78B	2.41B	3.31B
Total operating expenses	2.73B	3.32B	3.03B	3.70B
Operating income	1.17B	1.56B	2.09B	3.15B
Other non operating income	238.00K	4.37M	1.32M	8.58M
EBT including unusual items	1.41B	2.01B	2.34B	3.20B
EBT excluding unusual items	1.41B	2.01B	2.34B	3.20B
Income tax expense	-59.18M	536.45M	185.95M	668.64M
Effective tax rate	-4.19%	26.65%	7.96%	20.90%
Other operating expenses	-	-	-	-
Net income	1.47B	1.48B	2.15B	2.53B
Net profit margin	37.83%	30.24%	41.97%	36.90%
Earnings per share	3.60	3.58	5.21	6.13
Interest and investment income	123.73M	142.46M	139.53M	148.04M
Interest expense	-5.55M	-5.76M	-4.71M	-5.95M
Net interest expenses	118.18M	136.70M	134.82M	142.08M
Depreciation and amortization charges	-	-	-	-
EBITDA	1.20B	1.60B	2.14B	3.21B
Gain or loss from assets sale	-	1.50M	-	-

Finance